JPRN-UMIN000014658已完成未知
Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancer - JASPAC 06
Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)0 个研究点目标入组 329 人开始时间: 2014年7月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 329
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Histologically proven not to be a malignant pancreatic exocrine tumor 2) Not administered all of oxaliplatin, irinotecan, levofolinate calcium and fluorouracil
研究者
相似试验
已完成
不适用
Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting.Borderline resectable pancreatic cancerJPRN-UMIN000034509Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Center, Saitama Medical University30
尚未招募
2 期
Converison therapy of FOLFIRINOX in patients with unresectable locally advanced pancreatic cancer: A phase IInresectable locally advanced pancreatic cancerJPRN-UMIN000014039Yokohama City University50
招募中
2 期
eoadjuvant FOLFIRINOXPancreatic cancer, Neoadjuvant therapyPancreatic cancerJPRN-jRCT1041220027Yamashita Tatsuya50
招募中
不适用
Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastimnresectable pancreatic cancerJPRN-UMIN000028055Kanazawa University Hospital33
已完成
2 期
A phase II study of FOLFIRINOX in patients with advanced biliary tract cancerBiliary tract cancerJPRN-UMIN000020801Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo35